medigraphic.com
Revista Médica Sinergia

2019, Number 05

<< Back Next >>

Revista Médica Sinergia 2019; 4 (05)

Thromboembolic events and pregnancy: an update on anticoagulation in pregnant women

Camacho SAE, Méndez ZAM, Martín ZAC

Language: Spanish
References: 21
Page: 77-88
PDF size: 210.82 Kb.


ABSTRACT

Pregnancy is associated with multiple physiological and anatomical changes that make it a prothrombotic state. The combination of such factors results in a 5-fold increase in the risk for venous thromboembolism in these patients. There are multiple conditions, independent or related to pregnancy, in which there is an indication for pharmacological thromboprophylaxis or anticoagulation during pregnancy and the postpartum period. In order to start anticoagulant therapy in a pregnant woman the risks and benefits for both the woman and the fetus should be taken into consideration according to the time of gestation. Even though low molecular weight heparins are the treatment of choice for most indications, there are cases in which warfarin or direct oral anticoagulants are of use and may be the first line of treatment.


REFERENCES

  1. lshawabkeh L, Econocmy KE, Valente AM. Anticoagulation During Pregnancy: Evolving Strategies With a Focus on Mechanical Valves. J Am Coll Cardiol 2016; 68(16): 1804-1813. https://doi.org/10.1016/j.jacc.2016.06.076

  2. Gibson PS, Powrie R. Anticoagulants and pregnancy: When are they safe? Cleve Clin J Med 2009; 76(2): 113-27. https://doi.org/10.3949/ccjm.75a.072272

  3. American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. ACOG Practice Bulletin No. 196. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018; 132: e1-e17. https://doi.org/10.1097/AOG.0000000000002706

  4. Sucker C, Zotz R. Prophylaxis and treatment of venous thrombosis and pulmonary embolism in pregnancy. Reviews in Vascular Medicine. 2015; 3(2): 24-30. https://doi.org/10.1016/j.rvm.2015.05.003

  5. Scheres LJJ, Bistervels IM, Middeldorp S. Everything the clinician needs to know about evidencebased anticoagulation in pregnancy. Blood Rev. 2019; 33: 82-97 https://doi.org/10.1016/j.blre.2018.08.001

  6. Scheres LJJ, Bistervels IM, Middeldorp S . Everything the clinician needs to know about evidencebased anticoagulation in pregnancy. Blood Rev. 2019; 33:82-97. https://doi.org/10.1016/j.blre.2018.08.00

  7. Lim A, Samarage A, Lim B. Venous thromboembolism in pregnancy. Obstetrics, Gynaecology & Reproductive Medicine. 2016; 26(5): 133-139. https://doi.org/10.1016/j.ogrm.2016.02.005

  8. Fogerty AE. Challenges of Anticoagulation Therapy in Pregnancy. Curr Treat Options Cardio Med. 2017; 19(10): 1-13. https://doi.org/10.1007/s11936-017-0575-x

  9. Yarrington CD, Valente AM, Economy KE. Cardiovascular management in pregnancy: antithrombotic agents and antiplatelet agents. Circulation. 2015; 132: 1354-1364. https://doi.org/10.1161/CIRCULATIONAHA.114.003902

  10. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol. 2010; 115(6): 1256-1262. https://doi.org/10.1097/AOG.0b013e3181deba40

  11. Antovic A, Sennstrom M, Bremme K, Svenungsson E. Obstetric antiphospholipid syndrome. Lupus Sci Med. 2018; 5(1): e000197. https://doi.org/10.1136/lupus-2016-000197

  12. Ferreira J, Wipf J. Pharmacologic Therapies in Anticoagulation. Medical Clinics of North America. 2016; 100(4): 695-718. https://doi.org/10.1016/j.mcna.2016.03.007

  13. Breen K. Anticoagulation treatment. Medicine. 2017; 45(4): 239-243. https://doi.org/10.1016/j.mpmed.2017.01.010

  14. Hogg K, Weitz J. Goodman y Gilman: The Pharmacological Basis of Therapeutics. 13th edition. Blood coagulation and Anticoagulant, Fibrinolytic, and Antiplatlet Drugs. New York.: McGraw-Hill; c2018: 592-593 p.

  15. Blickstein D, Blickstein I. The risk of fetal loss associated with Warfarin anticoagulation. Int J Gynaecol Obstet 2002; 78(3): 221-225. https://doi.org/10.1016/S0020-7292(02)00186-8

  16. Richardson A, Shah S, Harris C, McCulloch G, Antoun P. Anticoagulation for the Pregnant Patient with Mechanical Heart Valve, No Perfect Therapy: Review of Guidelines for Anticoagulation in the Pregnant Patient. Case Rep Cardiol. 2017; 2017: ID3090273. https://doi.org/10.1155/2017/3090273

  17. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA/ACC Focused UPdate of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on ClinIcal Practice Guidelines. Circulation. 2017; 135(25): e1159-e1195. https://doi.org/10.1161/CIR.0000000000000503

  18. Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost. 2016; 14(8): 1673-1676. https://doi.org/10.1111/jth.13366

  19. Beyer-Westendorf J, Michalski F, Tittl L, Middeldorp S, Cohen H, Abdul Kadir R, et al. Pregnancy outcome in patients exposed to direct oral anticoagulants-and the challenge of event reporting. Thromb Haemost. 2016; 116(4): 651-658. https://doi.org/10.1160/TH16-04-0305

  20. DeCarolis S, di Pasquo RE, Del Sordo G, Buonomo A, Schiavino D, Lanzone A, et al. Fondaparinux in pregnancy: could it be a safe option? A review of the literature. Thromb Res. 2015; 135(6): 1049- 1051. https://doi.org/10.1016/j.thromres.2015.04.001

  21. Mauermann E et al. Heparin-induced thrombocytopenia in pregnancy: an interdisciplinary challengea case report and literature review. Int J Obstet Anesth. 2016; 26: 79-82. https://doi.org/10.1016/j.ijoa.2015.11.009




2020     |     www.medigraphic.com